Please use this identifier to cite or link to this item:
https://dspace.iiti.ac.in/handle/123456789/9053
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, Ajeet | en_US |
dc.contributor.author | Raghuvanshi, Abhinav | en_US |
dc.contributor.author | Mobin, Shaikh M. | en_US |
dc.contributor.author | Mathur, Pradeep | en_US |
dc.date.accessioned | 2022-03-17T01:00:00Z | - |
dc.date.accessioned | 2022-03-21T11:30:50Z | - |
dc.date.available | 2022-03-17T01:00:00Z | - |
dc.date.available | 2022-03-21T11:30:50Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Singh, A., Kumari, P., Raghuvanshi, A., Mobin, S. M., & Mathur, P. (2018). Ferrocene-substituted bis(ethynyl)anthracene compounds as anticancer agents. Applied Organometallic Chemistry, 32(2) doi:10.1002/aoc.4071 | en_US |
dc.identifier.issn | 0268-2605 | - |
dc.identifier.other | EID(2-s2.0-85031431098) | - |
dc.identifier.uri | https://doi.org/10.1002/aoc.4071 | - |
dc.identifier.uri | https://dspace.iiti.ac.in/handle/123456789/9053 | - |
dc.description.abstract | Three compounds (1–3) were synthesized, where ethynylferrocene is substituted at different positions of anthracene and anthraquinone, and their biological properties were investigated. Compounds 1–3 were characterized using NMR and mass spectroscopies and confirmed by their single-crystal X-ray structure. They were also characterized from electronic and photophysical properties. All three crystal structures were optimized using density functional theory calculations. The presence of C–H⋅⋅⋅π interactions in 1–3 leads to the formation of two- and three-dimensional networks. The bioactivity of 1–3 was expressed by molecular docking with various cancerous proteins, which participated in progression of cancer. Compound 2 displayed the best interaction with cancer-related Aurora A protein in terms of both binding energy (−10.61 kcal mol−1) as well as inhibition constant (16.74 nM). The molecular docking result also coincides with cytotoxicity on cancer cell lines (A375, HeLa) and DNA/protein binding affinity. Copyright © 2017 John Wiley & Sons, Ltd. | en_US |
dc.language.iso | en | en_US |
dc.publisher | John Wiley and Sons Ltd | en_US |
dc.source | Applied Organometallic Chemistry | en_US |
dc.subject | Anthracene | en_US |
dc.subject | Binding energy | en_US |
dc.subject | Bins | en_US |
dc.subject | Cell culture | en_US |
dc.subject | Crystal structure | en_US |
dc.subject | Cytotoxicity | en_US |
dc.subject | Diseases | en_US |
dc.subject | Ketones | en_US |
dc.subject | Mass spectrometry | en_US |
dc.subject | Molecular modeling | en_US |
dc.subject | Organometallics | en_US |
dc.subject | Proteins | en_US |
dc.subject | Single crystals | en_US |
dc.subject | Antiproliferative effect | en_US |
dc.subject | Centrosymmetric | en_US |
dc.subject | Chemotherapeutic | en_US |
dc.subject | Cytotoxic | en_US |
dc.subject | Incubation | en_US |
dc.subject | Density functional theory | en_US |
dc.title | Ferrocene-substituted bis(ethynyl)anthracene compounds as anticancer agents | en_US |
dc.type | Journal Article | en_US |
Appears in Collections: | Department of Chemistry |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Altmetric Badge: